What is the lowest intravenous dose of metoclopramide (Reglan)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lowest IV Reglan (Metoclopramide) Dose

The lowest intravenous dose of metoclopramide is 10 mg, administered slowly over 1-2 minutes. This is the standard minimum dose established by FDA labeling and supported across multiple clinical contexts 1.

FDA-Approved Dosing

The FDA drug label for Reglan IV explicitly states that 10 mg doses may be administered slowly by the intravenous route over a 1- to 2-minute period for diabetic gastroparesis 1. This same 10 mg dose is also the standard for:

  • Small bowel intubation (adults and pediatric patients >14 years): 10 mg IV over 1-2 minutes 1
  • Radiological examinations: 10 mg IV over 1-2 minutes 1
  • Postoperative nausea/vomiting: 10 mg IM/IV (though 20 mg may be used) 1

Context-Specific Dosing

For Nausea/Vomiting and Antiemetic Use

Multiple antiemetic guidelines consistently recommend 10 mg as the starting dose 2, 3, 4:

  • Low emetogenic chemotherapy: 10-40 mg PO or IV every 4-6 hours PRN 2
  • Breakthrough nausea: 10-40 mg PO or IV every 4-6 hours 2
  • Adjunctive migraine therapy: 10 mg IV or orally, administered 20-30 minutes before analgesics 4

The 2012 ESC heart failure guidelines mention 10 mg metoclopramide as part of acute heart failure management protocols 5, though this is an adjunctive use for nausea rather than primary therapy.

For High-Dose Chemotherapy Regimens

When used for highly emetogenic chemotherapy (cisplatin-based), doses escalate to 1-2 mg/kg per dose (typically 40-80 mg for average adults), but this represents specialized high-dose use, not the minimum effective dose 1.

Pediatric Dosing

For pediatric patients, weight-based dosing applies:

  • Ages 6-14 years: 2.5-5 mg IV 1
  • Under 6 years: 0.1 mg/kg IV 1

Critical Administration Details

Slow IV push is essential: The FDA label emphasizes administration over 1-2 minutes to minimize adverse effects, particularly hypotension 1. One case report documented sustained hypotension lasting 90 minutes after IV metoclopramide 10 mg, with systolic BP dropping from 138 to 84 mmHg 6. While rare, this underscores the importance of slow administration and blood pressure monitoring.

Renal Impairment Adjustment

For creatinine clearance <40 mL/min, initiate therapy at approximately one-half the recommended dosage (i.e., 5 mg instead of 10 mg) 1. Metoclopramide clearance is significantly reduced in renal impairment, with elimination half-life prolonged from the normal 5-6 hours 1, 7.

Common Pitfalls

  • Dystonic reactions: Monitor for extrapyramidal symptoms, particularly with repeated dosing. Have diphenhydramine 25-50 mg IV available for treatment 2
  • Avoid rapid IV push: Always administer over 1-2 minutes minimum
  • Drug accumulation: The pharmacokinetic data shows metoclopramide can accumulate with repeated dosing, particularly in neonates and patients with renal impairment 1

The evidence consistently supports 10 mg IV as the minimum effective dose for adults, with slower administration rates and dose reduction required for specific populations (pediatrics, renal impairment).

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.